Wednesday, November 25, 2009, 7:57am EST - Canadian Markets open in 1 hour and 33 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Qiagen NV (QGEN)

 On Nov 24: 21.36 USD   0.00 (0.00%)  
MORE ON QGEN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Qiagen N.V. (NasdaqNM:QGEN) Delayed quote dataEdit
Pre-Market: 21.86 Up 0.50 (2.34%) as of 7:33am EST on 11/25/09
Last Trade: 21.36 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 21.36
Open: N/A
Bid: 21.88 x 1000
Ask: 21.90 x 100
1y Target Est: 23.41
Day's Range: N/A - N/A
52wk Range: 14.32 - 23.58
Volume: 22,000
Avg Vol (3m): 1,163,000
Market Cap: 4.94B
P/E (ttm): 63.95
EPS (ttm): 0.33
Div & Yield: N/A (N/A%)
Qiagen NV (QGEN)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add QGEN to Portfolio   Download Data

HEADLINES
• Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Fri, Nov 20)
• Q3 2009 Qiagen N.V. Earnings Release - Time Not Supplied
CCBN (Tue, Nov 10)
• QIAGEN to Acquire SABiosciences
Marketwire (Mon, Nov 9)
• UPDATE - Qiagen beats estimates, tweaks outlook on test sales
at Reuters (Mon, Nov 9)
• Healthcare Bill Will Be Law By New Year Says Morningstar Strategist
Wall Street Transcript (Mon, Nov 9)
• [$$] Stocks Jump Despite Rising Unemployment
at Barrons.com (Sat, Nov 7)
• QIAGEN and British Veterinary Laboratories Agency Expand Partnership in Veterinary Testing
Business Wire (Thu, Nov 5)
• Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2009 Financial Results Call Set for November 10
PRNewswire (Tue, Nov 3)
• Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst
Wall Street Transcript (Tue, Oct 20)
• Coverage initiated on Qiagen by Barclays Capital
Briefing.com (Wed, Oct 7)
More Headlines for QGEN...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.2
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
QIAGEN N.V., through its subsidiaries, engages in the development, manufacture, and marketing of products for the handling, separation, purification, and subsequent use of nucleic acids and proteins.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices